{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,4]],"date-time":"2026-09-04T04:53:44Z","timestamp":1788497624765,"version":"build-2803163510"},"reference-count":99,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,2,27]],"date-time":"2026-02-27T00:00:00Z","timestamp":1772150400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,2,27]],"date-time":"2026-02-27T00:00:00Z","timestamp":1772150400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Mol Biol Rep"],"published-print":{"date-parts":[[2026,12]]},"DOI":"10.1007\/s11033-026-11586-4","type":"journal-article","created":{"date-parts":[[2026,2,27]],"date-time":"2026-02-27T11:58:40Z","timestamp":1772193520000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["From bench to bedside: stem cell therapy as a transformative approach against HIV"],"prefix":"10.1007","volume":"53","author":[{"given":"Ankit Kumar","family":"Bharti S","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anirban Goutam","family":"Mukherjee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abilash Valsala","family":"Gopalakrishnan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Babu","family":"Gajendran","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rahul","family":"Vashishth","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sabina Evan","family":"Prince","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,2,27]]},"reference":[{"key":"11586_CR1","doi-asserted-by":"publisher","unstructured":"Sepkowitz KA (2001) AIDS \u2014 The First 20 Years, New England Journal of Medicine\u00a0344(23):1764\u20131772. https:\/\/doi.org\/10.1056\/NEJM200106073442306","DOI":"10.1056\/NEJM200106073442306"},{"key":"11586_CR2","unstructured":"WHO (2026) HIV data and statistics. Accessed: Jan. 30, [Online]. Available: https:\/\/www.who.int\/teams\/global-hiv-hepatitis-and-stis-programmes\/hiv\/strategic-information\/hiv-data-and-statistics"},{"key":"11586_CR3","doi-asserted-by":"publisher","unstructured":"Aiuti A et al (2009) Gene therapy for immunodeficiency due to adenosine deaminase deficiency, New England Journal of Medicine 360(5):447\u2013458.\u00a0https:\/\/doi.org\/10.1056\/NEJMoa0805817","DOI":"10.1056\/NEJMoa0805817"},{"key":"11586_CR4","doi-asserted-by":"publisher","unstructured":"Nujhat Tasnim K, Haque Adrita S, Hossain S, Zaman Akash S, Sharker S (2020) The prospect of stem cells for hiv and cancer treatment: a review, Pharmaceutical and Biomedical Research, https:\/\/doi.org\/10.18502\/pbr.v6i1.3423","DOI":"10.18502\/pbr.v6i1.3423"},{"key":"11586_CR5","doi-asserted-by":"crossref","unstructured":"Lemey P et al (Feb. 2007) Synonymous substitution rates predict hiv disease progression as a result of underlying replication dynamics. PLoS Comput Biol 3(2):e29. doi:10.1371\/journal.pcbi.0030029","DOI":"10.1371\/journal.pcbi.0030029"},{"key":"11586_CR6","doi-asserted-by":"publisher","unstructured":"Miki S et al (Mar. 2022) Sustainable antiviral efficacy of rejuvenated hiv-specific cytotoxic t lymphocytes generated from induced pluripotent stem cells. J Virol 96(6). https:\/\/doi.org\/10.1128\/jvi.02217-21","DOI":"10.1128\/jvi.02217-21"},{"key":"11586_CR7","doi-asserted-by":"publisher","unstructured":"Turk G et al (2022) A possible sterilizing cure of hiv-1 infection without stem cell transplantation, Ann Intern Med\u00a0175(1):95\u2013100. https:\/\/doi.org\/10.7326\/L21-0297","DOI":"10.7326\/L21-0297"},{"key":"11586_CR8","doi-asserted-by":"publisher","unstructured":"Yukl SA et al (2010) Effect of raltegravir-containing intensification on HIV burden and T-cell activation in multiple gut sites of HIV-positive adults on suppressive antiretroviral therapy, AIDS\u00a024(16):2451\u20132460. https:\/\/doi.org\/10.1097\/QAD.0b013e32833ef7bb","DOI":"10.1097\/QAD.0b013e32833ef7bb"},{"key":"11586_CR9","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1146\/annurev-med-042909-093756","volume":"62","author":"SG Deeks","year":"2011","unstructured":"Deeks SG (2011) HIV infection, inflammation, immunosenescence, and aging. Annu Rev Med 62:141\u201355. https:\/\/doi.org\/10.1146\/annurev-med-042909-093756","journal-title":"Annu Rev Med"},{"key":"11586_CR10","doi-asserted-by":"publisher","unstructured":"Volberding PA, Deeks SG (Jul. 2010) Antiretroviral therapy and management of HIV infection. Lancet 376(9734):49\u201362. https:\/\/doi.org\/10.1016\/S0140-6736(10)60676-9","DOI":"10.1016\/S0140-6736(10)60676-9"},{"key":"11586_CR11","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.17507","author":"K Khalid","year":"2021","unstructured":"Khalid K et al (2021) Stem cell therapy and its significance in HIV infection. Cureus. https:\/\/doi.org\/10.7759\/cureus.17507","journal-title":"Cureus"},{"key":"11586_CR12","doi-asserted-by":"publisher","unstructured":"Page MJ et al (2021) The PRISMA 2020 statement: an updated guideline for reporting systematic reviews, BMJ n71. https:\/\/doi.org\/10.1136\/bmj.n71","DOI":"10.1136\/bmj.n71"},{"key":"11586_CR13","doi-asserted-by":"publisher","unstructured":"Xiao Q, Guo D, Chen S (Mar. 2019) Application of CRISPR\/Cas9-based gene editing in HIV-1\/AIDS therapy. Front Cell Infect Microbiol 9. https:\/\/doi.org\/10.3389\/fcimb.2019.00069","DOI":"10.3389\/fcimb.2019.00069"},{"key":"11586_CR14","doi-asserted-by":"publisher","unstructured":"Naif HM (2013) Pathogenesis of HIV Infection., Infect Dis Rep. 5(Suppl 1):e6. https:\/\/doi.org\/10.4081\/idr.2013.s1.e6","DOI":"10.4081\/idr.2013.s1.e6"},{"key":"11586_CR15","doi-asserted-by":"publisher","unstructured":"Swanstrom R, Coffin J (Dec. 2012) HIV-1 pathogenesis: the virus. Cold Spring Harb Perspect Med 2(12):a007443\u2013a007443. https:\/\/doi.org\/10.1101\/cshperspect.a007443","DOI":"10.1101\/cshperspect.a007443"},{"key":"11586_CR16","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejphar.2022.175173","volume":"931","author":"R Jena","year":"2022","unstructured":"Jena R et al (2022) Treatment strategies for HIV infection with emphasis on role of CRISPR\/Cas9 gene: success so far and road ahead. Eur J Pharmacol 931:175173. https:\/\/doi.org\/10.1016\/j.ejphar.2022.175173","journal-title":"Eur J Pharmacol"},{"key":"11586_CR17","doi-asserted-by":"publisher","unstructured":"Grande F et al (Feb. 2019) CCR5\/CXCR4 dual antagonism for the improvement of hiv infection therapy. Molecules 24(3):550. https:\/\/doi.org\/10.3390\/molecules24030550","DOI":"10.3390\/molecules24030550"},{"key":"11586_CR18","doi-asserted-by":"publisher","unstructured":"Simon V, Ho DD, Abdool Karim Q (2006) HIV\/AIDS epidemiology, pathogenesis, prevention, and treatment. Lancet 368(9534):489\u2013504. https:\/\/doi.org\/10.1016\/S0140-6736(06)69157-5","DOI":"10.1016\/S0140-6736(06)69157-5"},{"key":"11586_CR19","doi-asserted-by":"publisher","unstructured":"Marcello A (2006) Latency: the hidden HIV-1 challenge, Retrovirology 3(1):7. https:\/\/doi.org\/10.1186\/1742-4690-3-7","DOI":"10.1186\/1742-4690-3-7"},{"key":"11586_CR20","doi-asserted-by":"publisher","unstructured":"Chen J et al (Jul. 2022) The reservoir of latent HIV. Front Cell Infect Microbiol 12. https:\/\/doi.org\/10.3389\/fcimb.2022.945956","DOI":"10.3389\/fcimb.2022.945956"},{"key":"11586_CR21","doi-asserted-by":"publisher","unstructured":"Khanal S, Schank M, Gazzar ME, Moorman JP, Yao ZQ (Feb. 2021) HIV-1 latency and viral reservoirs: existing reversal approaches and potential technologies, targets, and pathways involved in hiv latency studies. Cells 10(2):475. https:\/\/doi.org\/10.3390\/cells10020475","DOI":"10.3390\/cells10020475"},{"key":"11586_CR22","doi-asserted-by":"publisher","unstructured":"Dahabieh MS, Battivelli E, Verdin E (Jan. 2015) Understanding HIV latency: the road to an hiv cure. Annu Rev Med 66(1):407\u2013421. https:\/\/doi.org\/10.1146\/annurev-med-092112-152941","DOI":"10.1146\/annurev-med-092112-152941"},{"key":"11586_CR23","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1016\/j.coi.2016.05.015","volume":"42","author":"JT Kimata","year":"2016","unstructured":"Kimata JT, Rice AP, Wang J (2016) Challenges and strategies for the eradication of the HIV reservoir. Curr Opin Immunol 42:65\u201370. https:\/\/doi.org\/10.1016\/j.coi.2016.05.015","journal-title":"Curr Opin Immunol"},{"issue":"9903","key":"11586_CR24","doi-asserted-by":"publisher","first-page":"1525","DOI":"10.1016\/S0140-6736(13)61809-7","volume":"382","author":"SG Deeks","year":"2013","unstructured":"Deeks SG, Lewin SR, Havlir DV (2013) The end of AIDS: HIV infection as a chronic disease. Lancet 382(9903):1525\u20131533. https:\/\/doi.org\/10.1016\/S0140-6736(13)61809-7","journal-title":"Lancet"},{"issue":"9624","key":"11586_CR25","doi-asserted-by":"publisher","first-page":"1603","DOI":"10.1016\/S0140-6736(08)60693-5","volume":"371","author":"A Jahn","year":"2008","unstructured":"Jahn A et al (2008) Population-level effect of HIV on adult mortality and early evidence of reversal after introduction of antiretroviral therapy in Malawi. Lancet 371(9624):1603\u20131611. https:\/\/doi.org\/10.1016\/S0140-6736(08)60693-5","journal-title":"Lancet"},{"issue":"5","key":"11586_CR26","doi-asserted-by":"publisher","first-page":"363","DOI":"10.1016\/S1473-3099(11)70032-9","volume":"11","author":"L Wittkop","year":"2011","unstructured":"Wittkop L et al (2011) Effect of transmitted drug resistance on virological and immunological response to initial combination antiretroviral therapy for HIV (EuroCoord-CHAIN joint project): a European multicohort study. Lancet Infect Dis 11(5):363\u2013371. https:\/\/doi.org\/10.1016\/S1473-3099(11)70032-9","journal-title":"Lancet Infect Dis"},{"key":"11586_CR27","doi-asserted-by":"publisher","unstructured":"Mohamed H et al (2022) Targeting CCR5 as a component of an HIV-1 therapeutic strategy.\u00a0Frontiers Media S.A. https:\/\/doi.org\/10.3389\/fimmu.2021.816515","DOI":"10.3389\/fimmu.2021.816515"},{"key":"11586_CR28","doi-asserted-by":"publisher","unstructured":"H\u00fctter G et al (2009) Long-term control of HIV by CCR5 Delta32\/Delta32 stem-cell transplantation, New England Journal of Medicine\u00a0360(7):692\u2013698. https:\/\/doi.org\/10.1056\/NEJMoa0802905","DOI":"10.1056\/NEJMoa0802905"},{"key":"11586_CR29","doi-asserted-by":"publisher","unstructured":"Chatterjee A, Matsangos A, Latinovic OS, Heredia A, Silvestri G (2024) Advancing towards HIV-1 remission: Insights and innovations in stem cell therapies, Arch. Stem Cell Ther.\u00a05(1):5\u201313.\u00a0https:\/\/doi.org\/10.46439\/stemcell.5.020","DOI":"10.46439\/stemcell.5.020"},{"key":"11586_CR30","unstructured":"Yu M, Poeschla E, Wong-Staal F (1994) Progress towards gene therapy for HIV infection. Gene Ther\u00a01(1):13\u201326"},{"key":"11586_CR31","doi-asserted-by":"publisher","unstructured":"Pich\u00e9 A (1999) Gene therapy for HIV infections: Intracellular immunization. Can J Infect Dis.\u00a010(4):307\u201312. https:\/\/doi.org\/10.1155\/1999\/914379","DOI":"10.1155\/1999\/914379"},{"key":"11586_CR32","doi-asserted-by":"publisher","unstructured":"Zhen A, Kitchen S (2013) Stem-Cell-Based Gene Therapy for HIV Infection.\u00a0Viruses\u00a06(1):1\u201312. https:\/\/doi.org\/10.3390\/v6010001","DOI":"10.3390\/v6010001"},{"key":"11586_CR33","doi-asserted-by":"publisher","unstructured":"Chari S, Nguyen A, Saxe J (2018) Stem cells in the Clinic. Cell Stem Cell 22(6):781\u2013782. https:\/\/doi.org\/10.1016\/j.stem.2018.05.017","DOI":"10.1016\/j.stem.2018.05.017"},{"key":"11586_CR34","doi-asserted-by":"publisher","unstructured":"Kiem H-P, Jerome KR, Deeks SG, McCune JM (2012) Hematopoietic-stem-cell-based gene therapy for HIV disease. Cell Stem Cell 10(2):137\u2013147. https:\/\/doi.org\/10.1016\/j.stem.2011.12.015","DOI":"10.1016\/j.stem.2011.12.015"},{"key":"11586_CR35","doi-asserted-by":"publisher","unstructured":"Widjaya MA, Ju J-C, Lee S-D (2022) CRISPR-edited stem cell transplantation for HIV-related gene modification in vivo: a systematic review. Stem Cell Rev Rep 18(5):1743\u20131755. https:\/\/doi.org\/10.1007\/s12015-022-10345-9","DOI":"10.1007\/s12015-022-10345-9"},{"key":"11586_CR36","doi-asserted-by":"publisher","unstructured":"Chitena L, Masisi K, Masisi K, Kwape TE, Gaobotse G (2022) Application of stem cell therapy during the treatment of hiv\/aids and duchenne muscular dystrophy. Curr Stem Cell Res Ther 17(7):633\u2013647. https:\/\/doi.org\/10.2174\/1574888X16666210810104445","DOI":"10.2174\/1574888X16666210810104445"},{"key":"11586_CR37","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1016\/j.addr.2016.04.027","volume":"103","author":"O Pernet","year":"2016","unstructured":"Pernet O, Yadav SS, An DS (2016) Stem cell-based therapies for HIV\/AIDS. Adv Drug Deliv Rev 103:187\u2013201. https:\/\/doi.org\/10.1016\/j.addr.2016.04.027","journal-title":"Adv Drug Deliv Rev"},{"key":"11586_CR38","doi-asserted-by":"publisher","unstructured":"Brown TR (Jan. 2015) I Am the Berlin patient: a personal reflection. AIDS Res Hum Retroviruses 31(1):2\u20133. https:\/\/doi.org\/10.1089\/aid.2014.0224","DOI":"10.1089\/aid.2014.0224"},{"issue":"5","key":"11586_CR39","doi-asserted-by":"publisher","first-page":"e340","DOI":"10.1016\/S2352-3018(20)30069-2","volume":"7","author":"RK Gupta","year":"2020","unstructured":"Gupta RK et al (2020) Evidence for HIV-1 cure after CCR5\u039432\/\u039432 allogeneic haemopoietic stem-cell transplantation 30 months post analytical treatment interruption: a case report. Lancet HIV 7(5):e340\u2013e347. https:\/\/doi.org\/10.1016\/S2352-3018(20)30069-2","journal-title":"Lancet HIV"},{"issue":"3","key":"11586_CR40","doi-asserted-by":"publisher","first-page":"583","DOI":"10.1038\/s41591-023-02213-x","volume":"29","author":"B-E Jensen","year":"2023","unstructured":"Jensen B-E et al (2023) In-depth virological and immunological characterization of HIV-1 cure after CCR5\u039432\/\u039432 allogeneic hematopoietic stem cell transplantation. Nat Med 29(3):583\u2013587. https:\/\/doi.org\/10.1038\/s41591-023-02213-x","journal-title":"Nat Med"},{"key":"11586_CR41","doi-asserted-by":"publisher","DOI":"10.1038\/nature.2013.12531","author":"EC Hayden","year":"2013","unstructured":"Hayden EC (2013) Infant\u2019s vanquished HIV leaves doctors puzzled. Nature https:\/\/doi.org\/10.1038\/nature.2013.12531","journal-title":"Nature\u00a0"},{"key":"11586_CR42","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-025-09893-0","author":"C Gaebler","year":"2025","unstructured":"Gaebler C et al (2025) Sustained HIV-1 remission after heterozygous CCR5\u220632 stem cell transplantation. Nature https:\/\/doi.org\/10.1038\/s41586-025-09893-0","journal-title":"Nature\u00a0"},{"key":"11586_CR43","doi-asserted-by":"publisher","unstructured":"Ye L et al (2014) Seamless modification of wild-type induced pluripotent stem cells to the natural CCR5\u220632 mutation confers resistance to HIV infection, Proceedings of the National Academy of Sciences111(26):9591\u20139596. https:\/\/doi.org\/10.1073\/pnas.1407473111","DOI":"10.1073\/pnas.1407473111"},{"key":"11586_CR44","doi-asserted-by":"publisher","unstructured":"Taylor JP, Cash MN, Santostefano KE, Nakanishi M, Terada N, Wallet MA (2018) CRISPR\/Cas9 knockout of USP18 enhances type I IFN responsiveness and restricts HIV-1 infection in macrophages. J Leukoc Biol 103(6):1225\u20131240. https:\/\/doi.org\/10.1002\/JLB.3MIA0917-352R","DOI":"10.1002\/JLB.3MIA0917-352R"},{"key":"11586_CR45","doi-asserted-by":"publisher","unstructured":"N. J, H. T, and S. J\u00a0(2022) IPSC-derived models in Africa: An HIV perspective, Biochimie 196:153\u2013160. https:\/\/doi.org\/10.1016\/j.biochi.2022.01.013","DOI":"10.1016\/j.biochi.2022.01.013"},{"key":"11586_CR46","doi-asserted-by":"publisher","DOI":"10.1093\/jleuko\/qiaf018","author":"K Saiprayong","year":"2025","unstructured":"Saiprayong K et al (2025) Development of 2LTRZFP-expressing induced pluripotent stem cells as a potential anti-HIV-1 gene therapy against viral integration. J Leukoc Biol. https:\/\/doi.org\/10.1093\/jleuko\/qiaf018","journal-title":"J Leukoc Biol"},{"key":"11586_CR47","doi-asserted-by":"crossref","unstructured":"Teque F et al Genetically-edited induced pluripotent stem cells derived from HIV-1-infected patients on therapy can give rise to immune cells resistant to HIV-1 infection. AIDS\u00a034(8):2020 [Online]. Available: https:\/\/journals.lww.com\/aidsonline\/fulltext\/2020\/07010\/genetically_edited_induced_pluripotent_stem_cells.5.aspx","DOI":"10.1097\/QAD.0000000000002539"},{"issue":"4","key":"11586_CR48","doi-asserted-by":"publisher","DOI":"10.3390\/pathogens10040409","volume":"10","author":"C Harrell","year":"2021","unstructured":"Harrell C, Popovska Jovicic B, Djonov V, Volarevic V (2021) Molecular mechanisms responsible for mesenchymal stem cell-based treatment of viral diseases. Pathogens 10(4):409. https:\/\/doi.org\/10.3390\/pathogens10040409","journal-title":"Pathogens"},{"issue":"1","key":"11586_CR49","doi-asserted-by":"publisher","DOI":"10.1186\/1742-4690-8-3","volume":"8","author":"TZ Nazari-Shafti","year":"2011","unstructured":"Nazari-Shafti TZ et al (2011) Mesenchymal stem cell derived hematopoietic cells are permissive to HIV-1 infection. Retrovirology 8(1):3. https:\/\/doi.org\/10.1186\/1742-4690-8-3","journal-title":"Retrovirology"},{"issue":"8","key":"11586_CR50","doi-asserted-by":"publisher","first-page":"1283","DOI":"10.1097\/QAD.0b013e32835fab77","volume":"27","author":"Z Zhang","year":"2013","unstructured":"Zhang Z et al (2013) Safety and immunological responses to human mesenchymal stem cell therapy in difficult-to-treat HIV-1-infected patients. AIDS 27(8):1283\u20131293. https:\/\/doi.org\/10.1097\/QAD.0b013e32835fab77","journal-title":"AIDS"},{"issue":"1","key":"11586_CR51","doi-asserted-by":"publisher","DOI":"10.1038\/s41392-021-00607-2","volume":"6","author":"L Wang","year":"2021","unstructured":"Wang L et al (2021) Human umbilical cord mesenchymal stem cell transfusion in immune non-responders with AIDS: a multicenter randomized controlled trial. Signal Transduct Target Ther 6(1):217. https:\/\/doi.org\/10.1038\/s41392-021-00607-2","journal-title":"Signal Transduct Target Ther"},{"key":"11586_CR52","doi-asserted-by":"publisher","DOI":"10.1172\/jci.insight.149033","author":"MG Weber","year":"2021","unstructured":"Weber MG et al (2021) Gut germinal center regeneration and enhanced antiviral immunity by mesenchymal stem\/stromal cells in SIV infection. JCI Insight. https:\/\/doi.org\/10.1172\/jci.insight.149033","journal-title":"JCI Insight"},{"issue":"1","key":"11586_CR53","doi-asserted-by":"publisher","DOI":"10.1038\/srep02510","volume":"3","author":"H Ebina","year":"2013","unstructured":"Ebina H, Misawa N, Kanemura Y, Koyanagi Y (2013) Harnessing the CRISPR\/Cas9 system to disrupt latent HIV-1 provirus. Sci Rep 3(1):2510. https:\/\/doi.org\/10.1038\/srep02510","journal-title":"Sci Rep"},{"issue":"8","key":"11586_CR54","doi-asserted-by":"publisher","first-page":"2381","DOI":"10.1099\/vir.0.000139","volume":"96","author":"C Li","year":"2015","unstructured":"Li C et al (2015) Inhibition of HIV-1 infection of primary CD4\u2009+\u2009T-cells by gene editing of CCR5 using adenovirus-delivered CRISPR\/Cas9. J Gen Virol 96(8):2381\u20132393. https:\/\/doi.org\/10.1099\/vir.0.000139","journal-title":"J Gen Virol"},{"issue":"1","key":"11586_CR55","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-018-26190-1","volume":"8","author":"Y Ophinni","year":"2018","unstructured":"Ophinni Y, Inoue M, Kotaki T, Kameoka M (2018) CRISPR\/Cas9 system targeting regulatory genes of HIV-1 inhibits viral replication in infected T-cell cultures. Sci Rep 8(1):7784. https:\/\/doi.org\/10.1038\/s41598-018-26190-1","journal-title":"Sci Rep"},{"key":"11586_CR56","doi-asserted-by":"publisher","unstructured":"Li L et al (2013) Genomic Editing of the HIV-1 Coreceptor CCR5 in Adult Hematopoietic Stem and Progenitor Cells Using Zinc Finger Nucleases. Molecular Therapy\u00a021(6):1259\u20131269. https:\/\/doi.org\/10.1038\/mt.2013.65","DOI":"10.1038\/mt.2013.65"},{"key":"11586_CR57","doi-asserted-by":"publisher","unstructured":"Mandal PK et al (2014) Efficient Ablation of Genes in Human Hematopoietic Stem and Effector Cells using CRISPR\/Cas9. Cell Stem Cell 15(5):643\u2013652. https:\/\/doi.org\/10.1016\/j.stem.2014.10.004","DOI":"10.1016\/j.stem.2014.10.004"},{"key":"11586_CR58","doi-asserted-by":"publisher","unstructured":"Liu Z et al (2017) Genome editing of the HIV co-receptors CCR5 and CXCR4 by CRISPR-Cas9 protects CD4\u2009+\u2009T cells from HIV-1 infection. Cell Biosci 7(1):47. https:\/\/doi.org\/10.1186\/s13578-017-0174-2","DOI":"10.1186\/s13578-017-0174-2"},{"key":"11586_CR59","doi-asserted-by":"publisher","unstructured":"Osborn MJ et al (2016) Evaluation of TCR gene editing achieved by talens, crispr\/cas9, and megatal nucleases. Mol Ther 24(3):570\u2013581. https:\/\/doi.org\/10.1038\/mt.2015.197","DOI":"10.1038\/mt.2015.197"},{"key":"11586_CR60","doi-asserted-by":"publisher","unstructured":"Zhang J et al (2019) Comparison of gene editing efficiencies of CRISPR\/Cas9 and TALEN for generation of MSTN knock-out cashmere goats. Theriogenology 132:1\u201311. https:\/\/doi.org\/10.1016\/j.theriogenology.2019.03.029","DOI":"10.1016\/j.theriogenology.2019.03.029"},{"key":"11586_CR61","doi-asserted-by":"publisher","unstructured":"Smith C et al (2014) Whole-Genome sequencing analysis reveals high specificity of CRISPR\/Cas9 and TALEN-based genome editing in human iPSCs. Cell Stem Cell 15(1):12\u201313. https:\/\/doi.org\/10.1016\/j.stem.2014.06.011","DOI":"10.1016\/j.stem.2014.06.011"},{"key":"11586_CR62","doi-asserted-by":"publisher","unstructured":"Cui Z et al (2021) The comparison of ZFNs, TALENs, and SpCas9 by GUIDE-seq in HPV-targeted gene therapy. Mol Ther Nucleic Acids\u00a026:1466\u20131478.\u00a0https:\/\/doi.org\/10.1016\/j.omtn.2021.08.008","DOI":"10.1016\/j.omtn.2021.08.008"},{"key":"11586_CR63","doi-asserted-by":"publisher","unstructured":"Qu X et al (2013) Sep., Zinc-finger-nucleases mediate specific and efficient excision of HIV-1 proviral DNA from infected and latently infected human T cells, Nucleic Acids Res41(16): 7771\u20137782. https:\/\/doi.org\/10.1093\/nar\/gkt571","DOI":"10.1093\/nar\/gkt571"},{"key":"11586_CR64","doi-asserted-by":"publisher","unstructured":"Cradick TJ, Keck K, Bradshaw S, Jamieson AC, McCaffrey AP (2010) Zinc-finger nucleases as a novel therapeutic strategy for targeting hepatitis B virus DNAs. Mol Ther 18(5):947\u2013954. https:\/\/doi.org\/10.1038\/mt.2010.20","DOI":"10.1038\/mt.2010.20"},{"key":"11586_CR65","doi-asserted-by":"publisher","unstructured":"Holt N et al (2010) Human hematopoietic stem\/progenitor cells modified by zinc-finger nucleases targeted to CCR5 control HIV-1 in vivo. Nat Biotechnol\u00a028(8):839\u2013847. https:\/\/doi.org\/10.1038\/nbt.1663","DOI":"10.1038\/nbt.1663"},{"key":"11586_CR66","doi-asserted-by":"publisher","unstructured":"Tebas P et al (2014) Gene editing of CCR5 in autologous CD4 T cells of persons infected with HIV, New England Journal of Medicine\u00a0370(10):901\u2013910.\u00a0https:\/\/doi.org\/10.1056\/NEJMoa1300662","DOI":"10.1056\/NEJMoa1300662"},{"key":"11586_CR67","doi-asserted-by":"publisher","unstructured":"Bobbin ML, Burnett JC, Rossi JJ (2015) RNA interference approaches for treatment of HIV-1 infection. Genome Med 7(1):50. https:\/\/doi.org\/10.1186\/s13073-015-0174-y","DOI":"10.1186\/s13073-015-0174-y"},{"key":"11586_CR68","doi-asserted-by":"publisher","unstructured":"Rossi JJ (2006) RNAi As a Treatment for HIV-1 Infection. Biotechniques\u00a040(sup4). https:\/\/doi.org\/10.2144\/000112167","DOI":"10.2144\/000112167"},{"key":"11586_CR69","doi-asserted-by":"publisher","unstructured":"Surabhi RM, Gaynor RB (2002) RNA interference directed against viral and cellular targets inhibits human immunodeficiency virus type 1 replication. J Virol 76(24):12963\u201312973. https:\/\/doi.org\/10.1128\/JVI.76.24.12963-12973.2002","DOI":"10.1128\/JVI.76.24.12963-12973.2002"},{"key":"11586_CR70","doi-asserted-by":"publisher","unstructured":"Jacque J-M, Triques K, Stevenson M (2002) Modulation of HIV-1 replication by RNA interference, Nature 418(6896):435\u2013438. https:\/\/doi.org\/10.1038\/nature00896","DOI":"10.1038\/nature00896"},{"key":"11586_CR71","doi-asserted-by":"publisher","unstructured":"Shi B et al (2017) TALEN-mediated knockout of ccr5 confers protection against infection of human immunodeficiency virus. JAIDS J Acquir Immune Defic Syndr 74(2):229\u2013241. https:\/\/doi.org\/10.1097\/QAI.0000000000001190","DOI":"10.1097\/QAI.0000000000001190"},{"key":"11586_CR72","doi-asserted-by":"publisher","unstructured":"Benjamin R, Berges BK, Solis-Leal A, Igbinedion O, Strong CL, Schiller MR (2016) TALEN gene editing takes aim on HIV. Hum Genet 135(9):1059\u20131070. https:\/\/doi.org\/10.1007\/s00439-016-1678-2","DOI":"10.1007\/s00439-016-1678-2"},{"key":"11586_CR73","doi-asserted-by":"publisher","unstructured":"Romito M et al (Jan. 2021) Preclinical evaluation of a novel TALEN targeting CCR5 confirms efficacy and safety in conferring resistance to HIV-1 infection. Biotechnol J 16(1). https:\/\/doi.org\/10.1002\/biot.202000023","DOI":"10.1002\/biot.202000023"},{"key":"11586_CR74","doi-asserted-by":"publisher","unstructured":"Koo T, Lee J, Kim J-S (2015) Measuring and reducing off-target activities of programmable nucleases including CRISPR-Cas9. Mol Cells\u00a038(6):475\u2013481. https:\/\/doi.org\/10.14348\/molcells.2015.0103","DOI":"10.14348\/molcells.2015.0103"},{"key":"11586_CR75","doi-asserted-by":"publisher","unstructured":"Matsui Y, Miura Y (Dec. 2023) Advancements in cell-based therapies for HIV Cure. Cells 13(1):64. https:\/\/doi.org\/10.3390\/cells13010064","DOI":"10.3390\/cells13010064"},{"key":"11586_CR76","doi-asserted-by":"publisher","unstructured":"Mitsuyasu RT et al (2000) Prolonged survival and tissue trafficking following adoptive transfer of CD4\u03b6 gene-modified autologous CD4\u2009+\u2009and CD8\u2009+\u2009T cells in human immunodeficiency virus\u2013infected subjects.\u00a0Blood\u00a096(3):785\u2013793. https:\/\/doi.org\/10.1182\/blood.V96.3.785","DOI":"10.1182\/blood.V96.3.785"},{"key":"11586_CR77","doi-asserted-by":"publisher","unstructured":"Deeks SG et al (2002) A phase II randomized study of HIV-specific T-cell gene therapy in subjects with undetectable plasma viremia on combination antiretroviral therapy.\u00a0Molecular Therapy\u00a05(6):788\u2013797. https:\/\/doi.org\/10.1006\/mthe.2002.0611","DOI":"10.1006\/mthe.2002.0611"},{"key":"11586_CR78","doi-asserted-by":"publisher","DOI":"10.1172\/JCI150211","author":"B Liu","year":"2021","unstructured":"Liu B et al (2021) Broadly neutralizing antibody\u2013derived CAR T cells reduce viral reservoir in individuals infected with HIV-1. J Clin Invest. https:\/\/doi.org\/10.1172\/JCI150211","journal-title":"J Clin Invest"},{"key":"11586_CR79","doi-asserted-by":"publisher","unstructured":"Caskey M et al (2015) Viraemia suppressed in HIV-1-infected humans by broadly neutralizing antibody 3BNC117.\u00a0Nature\u00a0522(7557):487\u2013491. https:\/\/doi.org\/10.1038\/nature14411","DOI":"10.1038\/nature14411"},{"key":"11586_CR80","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1016\/j.trsl.2017.07.002","volume":"187","author":"MA Carrillo","year":"2017","unstructured":"Carrillo MA, Zhen A, Zack JA, Kitchen SG (2017) New approaches for the enhancement of chimeric antigen receptors for the treatment of HIV. Transl Res 187:83\u201392. https:\/\/doi.org\/10.1016\/j.trsl.2017.07.002","journal-title":"Transl Res"},{"key":"11586_CR81","doi-asserted-by":"publisher","unstructured":"Deng H et al (1996) Identification of a major co-receptor for primary isolates of HIV-1. Nature 381(6584):661\u2013666. https:\/\/doi.org\/10.1038\/381661a0","DOI":"10.1038\/381661a0"},{"key":"11586_CR82","doi-asserted-by":"publisher","unstructured":"Gupta PK, Saxena A (2021) HIV\/AIDS: current updates on the disease, treatment and prevention. Proceedings of the National Academy of Sciences, India Section B: Biological Sciences.\u00a091(3):495\u2013510. https:\/\/doi.org\/10.1007\/s40011-021-01237-y","DOI":"10.1007\/s40011-021-01237-y"},{"issue":"8","key":"11586_CR83","doi-asserted-by":"publisher","first-page":"515","DOI":"10.2165\/00128072-200204080-00004","volume":"4","author":"N Bhana","year":"2002","unstructured":"Bhana N, Ormrod D, Perry CM, Figgitt DP (2002) Zidovudine: a review of its use in the management of vertically-acquired pediatric HIV infection. Paediatr Drugs 4(8):515\u2013553. https:\/\/doi.org\/10.2165\/00128072-200204080-00004","journal-title":"Paediatr Drugs"},{"key":"11586_CR84","unstructured":"Zachary Edwards, Curtis J, Ingold, Azmat CE (2025) Zidovudine. Treasure Island (FL): StatPearls Publishing"},{"key":"11586_CR85","doi-asserted-by":"publisher","unstructured":"Summa V et al (2008) Discovery of raltegravir, a potent, selective orally bioavailable HIV-integrase inhibitor for the treatment of HIV-AIDS infection, J Med Chem.\u00a051(18):5843\u20135855. https:\/\/doi.org\/10.1021\/jm800245z","DOI":"10.1021\/jm800245z"},{"key":"11586_CR86","doi-asserted-by":"publisher","unstructured":"Ramanathan S, Mathias AA, German P, Kearney BP (2011) Clinical Pharmacokinetic and Pharmacodynamic Profile of the HIV Integrase Inhibitor Elvitegravir. Clin Pharmacokinet\u00a050(4): 229\u2013244. https:\/\/doi.org\/10.2165\/11584570-000000000-00000","DOI":"10.2165\/11584570-000000000-00000"},{"key":"11586_CR87","doi-asserted-by":"publisher","unstructured":"Mbhele N, Chimukangara B, Gordon M (2021) HIV-1 integrase strand transfer inhibitors: a review of current drugs, recent advances and drug resistance. Int J Antimicrob Agents 57(5):106343. https:\/\/doi.org\/10.1016\/j.ijantimicag.2021.106343","DOI":"10.1016\/j.ijantimicag.2021.106343"},{"key":"11586_CR88","doi-asserted-by":"publisher","unstructured":"Yoshinaga T et al (2015) Antiviral characteristics of GSK1265744, an HIV integrase inhibitor dosed orally or by long-acting injection. Antimicrob Agents Chemother 59(1):397\u2013406. https:\/\/doi.org\/10.1128\/AAC.03909-14","DOI":"10.1128\/AAC.03909-14"},{"key":"11586_CR89","doi-asserted-by":"publisher","unstructured":"Sax PE et al (2017) Bictegravir versus dolutegravir, each with emtricitabine and tenofovir alafenamide, for initial treatment of HIV-1 infection: a randomised, double-blind, phase 2 trial. Lancet HIV 4(4):e154\u2013e160. https:\/\/doi.org\/10.1016\/S2352-3018(17)30016-4","DOI":"10.1016\/S2352-3018(17)30016-4"},{"key":"11586_CR90","doi-asserted-by":"publisher","unstructured":"Madruga JV et al (2007) Efficacy and safety of TMC125 (etravirine) in treatment-experienced HIV-1-infected patients in DUET-1: 24-week results from a randomised, double-blind, placebo-controlled trial.\u00a0The Lancet\u00a0370(9581):29\u201338.\u00a0https:\/\/doi.org\/10.1016\/S0140-6736(07)61047-2","DOI":"10.1016\/S0140-6736(07)61047-2"},{"key":"11586_CR91","doi-asserted-by":"publisher","unstructured":"Cilento ME et al (2021) Development of Human Immunodeficiency Virus Type 1 Resistance to 4\u2032-Ethynyl-2-Fluoro-2\u2032-Deoxyadenosine Starting with Wild-Type or Nucleoside Reverse Transcriptase Inhibitor-Resistant Strains. Antimicrob. Agents Chemother\u00a065(12).\u00a0https:\/\/doi.org\/10.1128\/AAC.01167-21","DOI":"10.1128\/AAC.01167-21"},{"key":"11586_CR92","unstructured":"Ratanasuwan W, Werarak P, Koryakova A, Berzins B, Bichko V, Murphy R Pharmacokinetics of VM-1500 20\u00a0mg and 40\u00a0mg in Healthy and HIV-Infected Patients. 20th international AIDS conference (20\u201225 July 2014)Melbourne, Australia https:\/\/www.natap.org\/2014\/IAC\/IAC_108.htm"},{"key":"11586_CR93","doi-asserted-by":"publisher","unstructured":"Talwani R, Temesgen Z (2020) Doravirine: a new non-nucleoside reverse transcriptase inhibitor for the treatment of HIV infection. Drugs of Today\u00a056(2):113. https:\/\/doi.org\/10.1358\/dot.2020.56.2.3109966","DOI":"10.1358\/dot.2020.56.2.3109966"},{"key":"11586_CR94","doi-asserted-by":"publisher","unstructured":"Creagh T et al (2001) Safety and pharmacokinetics of single doses of (+)-calanolide A, a novel, naturally occurring nonnucleoside reverse transcriptase inhibitor, in healthy, human immunodeficiency virus-negative human subjects. Antimicrob Agents Chemother 45(5):1379\u20131386. https:\/\/doi.org\/10.1128\/AAC.45.5.1379-1386.2001","DOI":"10.1128\/AAC.45.5.1379-1386.2001"},{"key":"11586_CR95","doi-asserted-by":"publisher","unstructured":"Goebel F et al (2006) Short-term antiviral activity of TMC278 \u2013 a novel NNRTI \u2013 in treatment-naive HIV-1-infected subjects. AIDS 20(13):1721\u20131726. https:\/\/doi.org\/10.1097\/01.aids.0000242818.65215.bd","DOI":"10.1097\/01.aids.0000242818.65215.bd"},{"key":"11586_CR96","doi-asserted-by":"publisher","unstructured":"Markowitz M et al (2006) Antiretroviral Activity, Pharmacokinetics, and Tolerability of MK-0518, a Novel Inhibitor of HIV-1 Integrase, Dosed As Monotherapy for 10 Days in Treatment-Naive HIV-1-Infected Individuals.\u00a0JAIDS Journal of Acquired Immune Deficiency Syndromes\u00a043(5):509\u2013515. https:\/\/doi.org\/10.1097\/QAI.0b013e31802b4956","DOI":"10.1097\/QAI.0b013e31802b4956"},{"key":"11586_CR97","doi-asserted-by":"crossref","unstructured":"DeJesus E et al (2006) Antiviral activity, pharmacokinetics, and dose response of the HIV-1 integrase inhibitor GS-9137 (JTK-303) in treatment-naive and treatment-experienced patients, JAIDS Journal of Acquired Immune Deficiency Syndromes 43(1), [Online]. Available: https:\/\/journals.lww.com\/jaids\/fulltext\/2006\/09000\/antiviral_activity,_pharmacokinetics,_and_dose.1.aspx","DOI":"10.1097\/01.qai.0000233308.82860.2f"},{"issue":"5","key":"11586_CR98","doi-asserted-by":"publisher","first-page":"740","DOI":"10.1093\/infdis\/jis750","volume":"207","author":"JJ Eron","year":"2013","unstructured":"Eron JJ et al (2013) Safety and efficacy of dolutegravir in treatment-experienced subjects with raltegravir-resistant HIV type 1 infection: 24-week results of the VIKING study. J Infect Dis 207(5):740\u2013748. https:\/\/doi.org\/10.1093\/infdis\/jis750","journal-title":"J Infect Dis"},{"issue":"5","key":"11586_CR99","doi-asserted-by":"publisher","first-page":"192","DOI":"10.1310\/hct1405-192","volume":"14","author":"W Spreen","year":"2013","unstructured":"Spreen W et al (2013) Pharmacokinetics, safety, and monotherapy antiviral activity of GSK1265744, an HIV integrase strand transfer inhibitor. HIV Clin Trials 14(5):192\u2013203. https:\/\/doi.org\/10.1310\/hct1405-192","journal-title":"HIV Clin Trials"}],"container-title":["Molecular Biology Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11033-026-11586-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11033-026-11586-4","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11033-026-11586-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,27]],"date-time":"2026-02-27T11:58:43Z","timestamp":1772193523000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11033-026-11586-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,27]]},"references-count":99,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,12]]}},"alternative-id":["11586"],"URL":"https:\/\/doi.org\/10.1007\/s11033-026-11586-4","relation":{},"ISSN":["0301-4851","1573-4978"],"issn-type":[{"value":"0301-4851","type":"print"},{"value":"1573-4978","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,27]]},"assertion":[{"value":"20 October 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 February 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 February 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"442"}}